Arno Therapeutics
30 Two Bridges Road
Suite 270
Fairfield
New Jersey
07004
United States
Tel: 862-703-7170
Fax: 973-227-5759
Website: http://www.arnothera.com/
Email: info@arnothera.com
99 articles about Arno Therapeutics
-
Arno Therapeutics Is Shuttering Its Doors
12/22/2017
Arno Therapeutics is calling it quits. It sold off all its assets, with the final asset being the rights to Onapristone, which it sold to Context Biopharma. -
Arno Therapeutics Announces Plan To Deregister Its Common Stock
3/28/2017
-
Arno Therapeutics Announces Cancellation Of Special Meeting Of Stockholders
12/22/2016
-
Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update
11/15/2016
-
Arno Therapeutics Reports Second Quarter 2016 Financial And Business Update
8/23/2016
-
Arno Therapeutics Completes $2.8 Million Private Placement
8/16/2016
-
Arno Therapeutics Reports First Quarter 2016 Financial And Business Update
5/17/2016
-
Arno Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Business Update
3/31/2016
-
Arno Therapeutics Reports Third Quarter 2015 Financial Results And Business Update
11/17/2015
-
Arno Therapeutics Data Demonstrate AR-12 As Novel Antifungal Drug Against Common Finger And Toenail Fungus, Onychomycosis
10/29/2015
-
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
10/22/2015
-
Arno Therapeutics To Present Late-Breaking Abstract On AR-12 As Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains At 15th European AIDS Conference
9/25/2015
-
Arno Therapeutics' AR-13 Data Show Promise As Potential New Therapeutic Option For Cystic Fibrosis Patients With Serious Bacterial Infections
9/24/2015
-
Arno Therapeutics To Present Data On Trans-Fungal Delivery Of AR-12 At 2015 American Association Of Pharmaceutical Scientists (AAPS) Annual Exposition
9/21/2015
-
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity Of AR-12, Identified It As Lead Compound Of New Class Of Drugs
9/21/2015
-
Arno Therapeutics Release: AR-12 Abstracts Accepted For Podium Presentation And Three Posters At ICAAC/ICC Annual Meeting 2015
9/14/2015
-
Arno Therapeutics To Present At 17th Annual Rodman & Renshaw Conference
9/1/2015
-
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone In Prostate Cancer
8/18/2015
-
Arno Therapeutics Reports Second Quarter 2015 Financial Results And Business Update
8/17/2015
-
Arno Therapeutics Announces Issuance Of First Onapristone Patent
6/4/2015